학술논문

IREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in type 1 spinal muscular atrophy (SMA)
Document Type
Journal
Source
NEUROMUSCULAR DISORDERS; OCT 2021, 31 pS134-pS134, 1p. Supplement: 1
Subject
Language
English
ISSN
18732364